AZD-1480

Investigational

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C14H14ClFN8
Molecular Weight	348.766
Optical Activity	UNSPECIFIED
Defined Stereocenters	1 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

C[C@H](NC1=NC=C(Cl)C(NC2=NNC(C)=C2)=N1)C3=NC=C(F)C=N3

InChI

InChIKey=PDOQBOJDRPLBQU-QMMMGPOBSA-N

InChI=1S/C14H14ClFN8/c1-7-3-11(24-23-7)21-13-10(15)6-19-14(22-13)20-8(2)12-17-4-9(16)5-18-12/h3-6,8H,1-2H3,(H3,19,20,21,22,23,24)/t8-/m0/s1

HIDE SMILES / InChI

Molecular Formula	C14H14ClFN8
Molecular Weight	348.766
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	1 / 1
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/23847256https://www.ncbi.nlm.nih.gov/pubmed/22829094 | https://www.ncbi.nlm.nih.gov/pubmed/23847256
Curator's Comment: Description was created based on several sources, including http://www.pharmacodia.com/yaodu/html/v1/chemicals/9ae10fb573b7027df2bd5f4bfb02af75.html http://adisinsight.springer.com/drugs/800030336

AZD-1480 was being developed by AstraZeneca for the treatment of myeloproliferative disorders and solid tumours. AZD-1480 is a novel ATP-competitive JAK2 inhibitor with IC50 of 0.26 nM in a cell-free assay, selectivity against JAK3 and Tyk2, and to a smaller extent against JAK1. AZD-1480 had been in phase I clinical trials by AstraZeneca for the treatment of hepatocellular carcinoma and myelofibrosis. However, this study has been terminated for the safety and efficacy reasons in 2012.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Tyrosine-protein kinase JAK2 53 Target ID: CHEMBL2971 Sources: https://www.ncbi.nlm.nih.gov/pubmed/22829094 \| https://www.ncbi.nlm.nih.gov/pubmed/21138246	Inhibitor 8146
Tyrosine-protein kinase JAK2 53 Target ID: CHEMBL1075225 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19962667	Inhibitor 8146		0.26 nM [Ki]

Conditions

Condition	Modality	Highest Phase	Product
Solid tumors 142 Sources: https://www.ncbi.nlm.nih.gov/pubmed/23847256 https://clinicaltrials.gov/ct2/show/NCT01112397	Primary	Phase I 422	Unknown Approved Use Unknown
Myeloproliferative disorders 2 Sources: https://www.ncbi.nlm.nih.gov/pubmed/23847256 http://adisinsight.springer.com/drugs/800030336 https://clinicaltrials.gov/ct2/show/NCT00910728	Primary	Phase I 422	Unknown Approved Use Unknown
Primary myelofibrosis 6 Sources: https://clinicaltrials.gov/ct2/show/NCT00910728	Primary	Phase I 422	Unknown Approved Use Unknown
Post-polycythaemia vera 1 Sources: https://clinicaltrials.gov/ct2/show/NCT00910728	Primary	Phase I 422	Unknown Approved Use Unknown
Essential thrombocythemia 1 Sources: https://clinicaltrials.gov/ct2/show/NCT00910728	Primary	Phase I 422	Unknown Approved Use Unknown
Hepatocellular carcinoma 81 Sources: https://clinicaltrials.gov/ct2/show/NCT01219543	Primary	Phase I 422	Unknown Approved Use Unknown

AUC

Value	Dose	Co-administered	Analyte	Population
57.6 μM × h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/21138246	10 mg/kg single, oral dose: 10 mg/kg route of administration: Oral experiment type: SINGLE co-administered:		AZD-1480 plasma	Mus musculus population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
2 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/21138246	10 mg/kg single, oral dose: 10 mg/kg route of administration: Oral experiment type: SINGLE co-administered:		AZD-1480 plasma	Mus musculus population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN

Overview

CYP3A4	CYP2C9	CYP2D6	hERG

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
P-gp 1401

Drug as perpetrator

Target	Modality	Activity	Metabolite	Clinical evidence
P-gp 1588	inhibitor 3185 Sources: https://pubchem.ncbi.nlm.nih.gov/bioassay/1346987#sid=363677143	yes

PubMed

Title	Date	PubMed
Potent and selective phosphopeptide mimetic prodrugs targeted to the Src homology 2 (SH2) domain of signal transducer and activator of transcription 3.	2011 May 26	21486047
Inhibition of STAT3 with orally active JAK inhibitor, AZD1480, decreases tumor growth in Neuroblastoma and Pediatric Sarcomas In vitro and In vivo.	2013 Mar	23531921

Patents

Sample Use Guides

In Vivo Use Guide

Thirty-eight patients with advanced malignancies were treated at doses of 10–70mgonce daily (QD) and 20–45 mg b.i.d. .

Route of Administration: Oral

In Vitro Use Guide

LN-17 cells were treated for 24 h with AZD1480 (0.05-1mkM) to determine whether Jak2 blockade can abrogate IL-6 dependent survival. Dose-dependent inhibition of pStat3Tyr705 and Stat3 DNA binding activity was observed in response to the addition of AZD1480, as was a loss of viability.

Substance Class	Chemical Created by `admin` on `Sat Dec 17 12:06:04 UTC 2022` Edited by `admin` on `Sat Dec 17 12:06:04 UTC 2022`
Record UNII	KL2Z2TLF01
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

AZD-1480

Common Name

English

AZD1480

Code

English

2,4-PYRIMIDINEDIAMINE, 5-CHLORO-N2-((1S)-1-(5-FLUORO-2-PYRIMIDINYL)ETHYL)-N4-(5-METHYL-1H-PYRAZOL-3-YL)-

Systematic Name

English

AZD 1480 [WHO-DD]

Common Name

English

Code System Code Type Description

FDA UNII

KL2Z2TLF01